Nearly a century after the crucial discovery of insulin, scientists of the Mohali-based National Institute of Pharmaceutical Education and Research (NIPER) have developed a long-sought insulin pill that could spare millions of diabetics around the world the pain of daily jabs.
In experiments with rats, the pill lowered blood glucose levels almost as much as injected insulin. The effects of the pill lasted longer than that of injected insulin, according to the study published in the American Chemical Society journal Biomacromolecules.
For years, researchers have sought a way to transform delivery of insulin therapy from a jab to a pill, but it has been a challenge. The body's digestive enzymes that are so good at breaking down food also break down insulin before it can get to work. In addition, insulin does not get easily absorbed through the gut into the bloodstream.
To overcome these hurdles, NIPER researchers combined two approaches to shield insulin from the digestive enzymes and then get it into the blood. The team, which included researchers Ashish Kumar Agrawal, Harshad Harde, Kaushik Thanki and Sanyog Jain, packaged insulin in tiny sacs made of lipids, or fats, called liposomes, which are already used in some treatments.
Then, they wrapped the liposomes in layers of protective molecules called polyelectrolytes.
To help these 'layersomes' get absorbed into the bloodstream, they attached folic acid, a kind of vitamin B that has been shown to help transport liposomes across the intestinal wall into the blood.
In rats, the delivery system lowered blood glucose levels almost as much as injected insulin, though the effects of the layersomes lasted longer than that of injected insulin.
An estimated 347 million people globally are living with diabetes, a condition where the body fails to utilise the ingested glucose properly. This could be due to lack of the hormone insulin or because the insulin that is available is not working effectively.
Diabetics must test their blood sugar several times a day, and need insulin jabs for the rest of their lives in order to maintain adequate levels of the hormone.
Patent filed in 2011
Mohali: The research was conducted under Sanyog Jain, assistant professor, department of pharmaceutics, NIPER. The patent was filed in 2011, while the study has been published now.
Institute director Dr KK Bhutani said, "It is one of the best research work of our institute, which will have an impact on global health care systems. We are proud of our faculty and students." NIPER was set up in Mohali in 1994.
(with inputs from HT Reporters)